Pulsed Field Ablation Market
授權報價
| Single User | $4,799 USD |
| Multi User | $7,999 USD |
| Enterprise / Global Site Licence | $17,999 USD |
完整報告名稱與涵蓋範圍
Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Area, Source of Ablation, Key Geographical Regions, and Sales Forecast of Leading Players – Trends and Forecast till 2035
報告摘要
PULSED FIELD ABLATION MARKET: OVERVIEW
As per Roots Analysis, the global pulsed field ablation market is estimated to grow from USD 3.2 billion in the current year to USD 14.6 billion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 18.4% during the forecast period.
Pulsed Field Ablation Market: Growth and Trends
Pulsed field ablation (PFA) is a non-thermal cardiac ablation modality that uses short, high-voltage electrical pulses to induce irreversible electroporation in target tissue. Unlike radiofrequency and cryoablation, which rely on heat or cold energy and carry a risk of collateral injury to structures such as the esophagus and phrenic nerve, PFA selectively targets myocardial cells while sparing surrounding tissue. This safety differentiation has made PFA one of the fastest-adopted technologies in electrophysiology over the past few years.
Clinical evidence supporting PFA continues to expand across multiple platforms and procedural workflows. For instance, Boston Scientific's FARAPULSE system has demonstrated strong symptomatic relief rates in treated atrial fibrillation patients. Moreover, several other systems from Medtronic, Biosense Webster, and emerging players have secured regulatory clearances in the US, Europe, and Asian countries. This growing base of approvals is accelerating clinical adoption and encouraging hospitals to invest in dedicated PFA-capable electrophysiology labs.
Further, the convergence of PFA with artificial intelligence-enabled electrophysiology workflows is an emerging area of interest. AI tools are increasingly being applied to improve patient selection, guide lesion delivery beyond standard pulmonary vein isolation, and streamline procedural planning. The integration of AI tools helps operators achieve more consistent outcomes while managing procedure time.
At the same time, evolving tariff and trade policies affecting medical device imports are prompting several manufacturers to localize or near-shore production of PFA generators, catheters, and related components within the US and Europe. This will help to reduce exposure to cross-border duties and supply chain disruption.
Growth Drivers: Factors Fueling Market Expansion
Growth in the pulsed field ablation market is driven by the rising global burden of atrial fibrillation. According to a Heart Rhythm Society article, atrial fibrillation affects around 40 million people worldwide, and the number of cases is likely to increase by 60% in 2050. As detection improves through wearable and remote monitoring technologies, the diagnosed patient pool requiring rhythm-control therapy continues to expand, creating sustained procedural demand.
Notably, PFA's tissue selectivity and non-thermal mechanism are core differentiators supporting its adoption over conventional thermal ablation techniques as it reduces complications and shortens procedure times. Beyond cardiology, device developers are adapting PFA platforms for tissue-selective tumour ablation near sensitive anatomical structures, such as liver, pancreas, prostate, kidney, and lung.
Expanding electrophysiology lab infrastructure and growing adoption of electroporation-based therapy and improving reimbursement frameworks are further reinforcing the long-term growth outlook of the market.
Market Challenges: Critical Barriers Hindering Progress
Despite strong growth momentum, the pulsed field ablation market faces several adoption barriers. PFA consoles and single-use catheters require a significantly higher upfront and per-procedure cost compared with established radiofrequency and cryoablation systems. High treatment expenses create affordability challenges for smaller hospitals, ambulatory surgical centres, and cost-constrained health systems.
Many public and smaller private hospitals also lack the capital budgets, dedicated electrophysiology labs, and procedural volumes needed to justify a new PFA platform. Therefore, the lack of dedicated labs is slowing broader rollout outside high-volume tertiary centres. Continued competition from well-established thermal ablation technologies, along with the need for further procedural standardization across newer PFA platforms, adds additional friction to near-term market expansion.
Pulsed Field Ablation Market: Key Insights
The report delves into the current state of the pulsed field ablation market and identifies potential growth opportunities within the industry, particularly from a distributor and channel-partner perspective. Some key findings include:
• Device manufacturers rely predominantly on direct sales forces and dedicated clinical specialist teams to commercialize pulsed field ablation systems in mature markets such as the US and Western Europe, which limits the near-term role of third-party distributors in these geographies.
• In Asia-Pacific, and Latin America manufacturers lacking established commercial infrastructure are increasingly relying on regional and national distribution partners to navigate local regulatory pathways and build hospital relationships, creating a distinct entry point for specialty medical device distributors.
• The extension of pulsed field technology into interventional oncology is creating new distribution entry points beyond electrophysiology, opening the door to distributors with existing interventional radiology and oncology channel relationships.
• Region-specific device registration requirements, including China's NMPA and Japan's PMDA pathways, extend onboarding timelines for new distribution partners even after a device secures its first regulatory approval in the US or Europe.
• Manufacturers are increasingly near-shoring or localizing production of generators and catheters in the US and Europe in response to evolving tariff and trade policy, a shift that is reshaping distributor sourcing strategies and inventory planning.
• Post-market evidence generation requirements, including registry participation and outcomes tracking, are pushing manufacturers to favour distribution partners capable of supporting structured data collection, particularly in newer expansion markets.
• Consolidation among large, established electrophysiology equipment distributors is raising the bar for entry, though niche regional distributors with condition-specific or catheter lab-specific expertise continue to find opportunities in underserved geographies.
Pulsed Field Ablation Market Segments
The market sizing and opportunity analysis has been segmented across the following parameters:
By Therapeutic Area
• Cardiovascular Disorders
• Dermatological Disorders
• Oncological Disorders
• Respiratory Disorders
By Product Components
• Catheters
• Generators
By Application Area
• Ablation
• Ablation and Mapping
By Source of Ablation
• Pulsed Field Energy
• Pulsed Field and Cryoablation Energy
• Pulsed Field and Radiofrequency Energy
By Geographical Regions
• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Australia
Pulsed Field Ablation Market: Key Segments
Cardiovascular Disorders Leads the Target Indication Segment
Based on our market assessment, the cardiovascular disorders segment currently accounts for the majority of the pulsed field ablation market and is expected to retain its leadership position throughout the forecast period. This dominance stems from the fact that PFA devices have achieved their highest level of clinical validation, regulatory approval, and commercial adoption in the treatment of atrial fibrillation and related arrhythmias. Growing procedural volumes, expanding electrophysiology infrastructure, and the availability of multiple commercially approved platforms continue to reinforce cardiovascular applications as the primary revenue-generating segment.
In contrast, the oncological disorders segment is expected to register the highest CAGR during the forecast period. This highest growth is supported by the transition of pulsed field technology from a predominantly cardiac tool towards a broader tissue-selective treatment platform. As irreversible electroporation continues to demonstrate promising outcomes in liver, pancreatic, prostate, kidney, and lung tumours, device manufacturers, research institutions, and healthcare providers are directing increasing investment toward this emerging application.
Catheter Dominates the Product Component Segment
Based on the product components, the catheter sub-segment is expected to continue capturing the majority of pulsed field ablation market revenue. This is primarily attributed to the single-use, consumable nature of PFA catheters, which follow a recurring, per-procedure revenue model in contrast to generators.
As the market matures, next-generation catheters that integrate mapping and ablation functionality into a single platform are expected to command higher average selling prices, which further accelerate this segment growth.
Ablation Remains the Leading Application, While Ablation and Mapping Gains Momentum
By application area, ablation-only configurations currently hold the largest share of the market. This highest share reflects the early focus on pulmonary vein isolation procedures where speed, reproducibility, and reduced fluoroscopy time are prioritized over integrated mapping. The shift toward treating more complex and persistent arrhythmia substrates will likely accelerate growth in the ablation and mapping segment. This growth is further fueled by hospital investments in integrated, single-platform electrophysiology ecosystems.
Pulsed Field Energy Dominates the Source of Ablation Segment
Based on the source of ablation, pure pulsed field energy platforms currently capture the majority of market share. This dominance is driven by the fundamental safety advantage pulsed field energy offers over thermal modalities. Notably, the standardization benefits of single-platform ecosystems that integrate catheter design, waveform optimization, and mapping compatibility, reduce training complexity for operators, making it a preferable choice in clinical settings.
North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region
According to our market projections, North America is expected to maintain its leadership in the pulsed field ablation market through 2035. This dominance is supported by early commercialization advantage, a dense concentration of electrophysiology-capable hospitals, rapid FDA-driven regulatory clearances, and a well-structured reimbursement framework for atrial fibrillation ablation procedures.
Asia-Pacific, on the other hand, is projected to register the highest CAGR during the forecast period. This growth is driven by rapidly improving healthcare infrastructure, growing investment in cardiac catheterization laboratories, expanding electrophysiology training programs, and a large, aging population base with a significant untreated atrial fibrillation burden across markets such as China, India, and South Korea.
Example Players in Pulsed Field Ablation Market
• AccuPulse Medical
• Acutus Medical
• Adagio Medical
• AngioDynamics
• Argá Medtech
• AtriAN Medical
• Biosense Webster (Johnson & Johnson MedTech)
• Boston Scientific
• CardioFocus
• CathRx
• CRC EP
• Galvanize Therapeutics
• Gradient Medical
• Hangzhou Dinova EP Technology
• Kardium
• Medtronic
• Mirai Medical
• Pulse Biosciences
Expert Interview and Industry Insights
The opinions and insights presented in this study were shaped by discussions conducted with multiple stakeholders across the pulsed field ablation ecosystem. The research report features detailed transcripts of interviews held with the following industry stakeholders:
• Co-Founder and Chief Executive Officer, Small Company, Switzerland
• Chief Medical Officer, Very Large Company, US
• Chief of Cardiac Surgery and Co-Director, Very Large Company, US
• Senior Vice President and President, Cardiac Rhythm Management and Diagnostics, Very Large Company, US
• President, and Vice President of Preclinical and Clinical Research and Medical Affairs, Very Large Company, New Zealand
• Managing Director, Large Company, US
• Managing Director, Very Large Company, US
• Director, Ventricular Tachycardia Program, Very Large Company, US
• Co-Director, Translational Research and Research Fellowship, Very Large Company, US
• Cardiologist, Very Large Company, US
PULSED FIELD ABLATION MARKET: RESEARCH COVERAGE
• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the pulsed field ablation market, focusing on key market segments, including therapeutic area, product components, application area, source of ablation, and geographical regions.
• Pulsed Field Ablation Devices Landscape: A detailed assessment of the overall device landscape, featuring information on parameters such as type of product component, application area, source of ablation, and regulatory approval status. Additionally, it features analysis of device developers based on year of establishment, company size, and location of headquarters.
• Company Profiles: In-depth profiles of prominent players engaged in offering pulsed field ablation systems, featuring information on year of establishment, location of headquarters, company size, management team, product portfolio, and key initiatives.
• Recent Developments: A detailed analysis of recent developments in this industry, including partnerships and collaborations, funding and investments, regulatory approvals, and product launches.
• Patent Analysis: An analysis of patents filed and granted related to pulsed field ablation devices, based on parameters such as type of patent, application and publication year, jurisdiction, CPC symbols, type of applicant, and patent valuation.
• Global Events Analysis: An in-depth assessment of global pulsed field ablation events, covering event trends by year, type, platform, and geography, along with analyses of key organizers, participating companies, speaker profiles, and emerging discussion themes to identify evolving industry priorities and networking opportunities.
• Strategic Partner Analysis: A comprehensive assessment of potential partnership opportunities for pulsed field ablation device developers, featuring a likelihood-based evaluation of cardiac mapping and navigation device companies based on predefined assumptions, key parameters, and proprietary partner selection methodology.
• Market Impact Analysis: The report also covers analyses of drivers, restraints, opportunities, and challenges affecting market growth.
Key Questions Answered in this Report
• Which are the leading companies in the pulsed field ablation market?
• Which region dominates the pulsed field ablation market, and which region is growing the fastest?
• What are the key trends observed in the pulsed field ablation market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by pulsed field ablation device developers and distributors?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?
• What distribution models are manufacturers using across mature and emerging markets?
Reasons to Buy this Report
This report has been specifically developed to support distributors, channel partners, and business development teams evaluating entry into the pulsed field ablation market.
• Comprehensive Secondary Research: Extensive analysis of company disclosures, regulatory databases, clinical trial registries, investor presentations, scientific literature, and industry publications to evaluate market trends, competitive landscape, and commercialization strategies.
• Primary Research Validation: Insights validated through interviews with senior executives, electrophysiologists, cardiac surgeons, and industry experts to strengthen market assumptions and forecast accuracy.
• Market and Commercial Analysis: Evaluation of product segmentation, revenue models (capital equipment and consumables), distribution channels, and regional commercialization strategies across key markets.
• Regulatory and Regional Assessment: Analysis of country-specific regulatory pathways, reimbursement environment, and market-entry considerations across North America, Europe, and Asia-Pacific.
• Forecasting Framework: Market forecasts developed using historical trends, demand analysis, primary validation, and scenario-based (conservative, base, and optimistic) forecasting, incorporating recent clinical evidence and regulatory developments.
Additional Benefits
• Complementary Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older
目錄 Table of Contents
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations in the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russia-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. mRNA Vaccines
6.2.1. Advantages of mRNA Vaccines
6.2.2. Key Applications of mRNA Vaccines
6.3. mRNA Vaccines
6.3.1. Advantages of mRNA Vaccines
6.3.2. Key Applications of mRNA Vaccines
6.4. mRNA Delivery Routes
6.5. mRNA Delivery Strategies
6.6. Key Challenges Associated with mRNA Vaccines
6.7. Future Perspectives
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. mRNA Vaccines: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Drug Candidate
7.2.3. Analysis by Type of Program
7.2.4. Analysis by Type of Delivery System
7.2.5. Analysis by Type of Molecule Encoded
7.2.6. Analysis by Route of Administration
7.2.7. Analysis by Therapeutic Area
7.3. mRNA Vaccines: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Developers: Analysis by Number of Drugs Developed
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. mRNA Vaccines: Product Competitiveness Analysis
8.4.1. mRNA Vaccines Developed by Players based in North America
8.4.2. mRNA Vaccines Developed by Players based in Europe
8.4.3. mRNA Vaccines Developed by Players based in Asia-Pacific and Rest of the World
9. COMPANY PROFILES: mRNA VACCINE DEVELOPERS BASED IN NORTH AMERICA
9.1. Chapter Overview
9.2. Leading Developers in mRNA Vaccines Market based in North America
9.2.1. Arcturus Therapeutics
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. mRNA Vaccines Portfolio
9.2.1.4. Recent Developments and Future Outlook
9.2.2. Immorna
9.2.2.1. Company Overview
9.2.2.2. mRNA Vaccines Portfolio
9.2.2.3. Recent Developments and Future Outlook
9.2.3. Moderna
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. mRNA Vaccines Portfolio
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Providence Therapeutics
9.2.4.1. Company Overview
9.2.4.2. Financial Information
9.2.4.3. mRNA Vaccines Portfolio
9.2.4.4. Recent Developments and Future Outlook
9.2.5. Innovac Therapeutics
9.2.5.1. Company Overview
9.2.5.2. mRNA Vaccines Portfolio
9.2.5.3. Recent Developments and Future Outlook
9.2.6. Kernal Biologics
9.2.6.1. Company Overview
9.2.6.2. Financial Information
9.2.6.3. mRNA Vaccines Portfolio
9.2.6.4. Recent Developments and Future Outlook
9.2.7. Recode Therapeutics
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. mRNA Vaccines Portfolio
9.2.7.4. Recent Developments and Future Outlook
9.2.8. Rejuvenation Technologies
9.2.8.1. Company Overview
9.2.8.2. Financial Information
9.2.8.3. mRNA Vaccines Portfolio
9.2.8.4. Recent Developments and Future Outlook
9.2.9. RNAimmune
9.2.9.1. Company Overview
9.2.9.2. Financial Information
9.2.9.3. mRNA Vaccines Portfolio
9.2.9.4. Recent Developments and Future Outlook
9.2.10. Turn Biotechnologies
9.2.10.1. Company Overview
9.2.10.2. Financial Information
9.2.10.3. mRNA Vaccines Portfolio
9.2.10.4. Recent Developments and Future Outlook
9.2.11. Strand Therapeutics
9.2.11.1. Company Overview
9.2.11.2. Financial Information
9.2.11.3. mRNA Vaccines Portfolio
9.2.11.4. Recent Developments and Future Outlook
10. COMPANY PROFILES: mRNA VACCINE DEVELOPERS BASED IN EUROPE
10.1. Chapter Overview
10.2. Leading Developers in mRNA Vaccines Market based in North America
10.2.1. BioNTech
10.2.1.1. Company Overview
10.2.1.2. Financial Information
10.2.1.3. mRNA Vaccines Portfolio
10.2.1.4. Recent Developments and Future Outlook
10.2.2. CureVac
10.2.2.1. Company Overview
10.2.2.2. Financial Information
10.2.2.3. mRNA Vaccines Portfolio
10.2.2.4. Recent Developments and Future Outlook
10.2.3. Ethris
10.2.3.1. Company Overview
10.2.3.2. mRNA Vaccines Portfolio
10.2.3.3. Recent Developments and Future Outlook
11. COMPANY PROFILES: mRNA VACCINE DEVELOPERS BASED IN ASIA-PACIFIC
11.1. Chapter Overview
11.2. Leading Developers in mRNA Vaccines Market based in North America
11.2.1. Suzhou Abogen Biosciences
11.2.1.1. Company Overview
11.2.1.2. mRNA Vaccines Portfolio
11.2.1.3. Recent Developments and Future Outlook
11.2.2. Gennova Biopharmaceuticals
11.2.2.1. Company Overview
11.2.2.2. Financial Information
11.2.2.3. mRNA Vaccines Portfolio
11.2.2.4. Recent Developments and Future Outlook
11.2.3. RNACure
11.2.3.1. Company Overview
11.2.3.2. mRNA Vaccines Portfolio
11.2.3.3. Recent Developments and Future Outlook
11.2.4. Walvax
11.2.4.1. Company Overview
11.2.4.2. Financial Information
11.2.4.3. mRNA Vaccines Portfolio
11.2.4.4. Recent Developments and Future Outlook
12. BIG PHARMA INITIATIVES
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. mRNA Vaccines Market: Big Player Initiatives
12.3.1. Analysis by Year of Initiative
12.3.2. Analysis by Type of Initiative
12.3.3. Analysis by Year and Type of Initiative
12.3.4. Analysis by Type of Partnership
12.3.5. Analysis by Type of Expansion
12.3.6. Analysis by Year of Initiative and Company
12.3.7. Big Pharma Players: Analysis by Number of Initiatives
12.4. Benchmarking Analysis: Big Pharma Players
12.4.1. Spider Web Analysis: Bayer
12.4.2. Spider Web Analysis: Pfizer
12.4.3. Spider Web Analysis: Sanofi
12.5. Concluding Remarks
13. START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Start-ups focused on mRNA Vaccines
13.3. Benchmarking of Start-ups
13.4. Startup-Health Indexing
13.4.1. Analysis by Location of Headquarters
13.4.2. Analysis by Company Strength
13.4.3. Analysis by Pipeline Maturity
13.4.4. Analysis by Pipeline Strength
13.4.5. Analysis by Financial Support
13.4.6. Analysis by Investor Strength
13.4.7. Analysis by Partnership Activity
13.4.8. Start-ups Health Indexing: Roots Analysis Perspective
14. CLINICAL TRIAL ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. mRNA Vaccines: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
14.3.3. Analysis by Trial Phase
14.3.4. Analysis of Number of Patients Enrolled by Trial Phase
14.3.5. Analysis by Trial Status
14.3.6. Analysis by Trial Registration Year and Trial Status
14.3.7. Analysis by Patient Gender
14.3.8. Analysis by Study Design
14.3.8.1. Analysis by Type of Allocation
14.3.8.2. Analysis by Type of Intervention Model
14.3.8.3. Analysis by Type of Masking
14.3.8.4. Analysis by Trial Purpose
14.3.9. Analysis by Type of Sponsor / Collaborator
14.3.10. Analysis by Geography
14.3.10.1. Analysis of Clinical Trials by Geography
14.3.10.2. Analysis of Clinical Trials by Geography and Trial Status
14.3.10.3. Analysis of Patients Enrolled by Geography and Trial Status
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. mRNA Vaccines Market: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Therapeutic Area
15.3.5. Most Active Players: Analysis by Number of Partnerships
15.3.6. Analysis by Geography
15.3.6.1. Intercontinental and Intracontinental Agreements
15.3.6.2. Local and International Agreements
16. FUNDING AND INVESTMENTS
16.1. Chapter Overview
16.2. Funding Models
16.3. mRNA Vaccines Market: Funding and Investment Analysis
16.3.1. Analysis by Year of Funding
16.3.1.1. Cumulative Year-wise Trend of Funding Instances
16.3.1.2. Cumulative Year-wise Trend of Amount Invested
16.3.2. Analysis by Type of Funding
16.3.2.1. Analysis of Funding Instances
16.3.2.2. Analysis of Amount Invested
16.3.3. Analysis by Year and Type of Funding
16.3.4. Analysis by Amount Raised by Year and Type of Funding
16.3.5. Analysis by Therapeutic Area
16.3.6. Most Active Players: Analysis by Number of Funding Instances
16.3.7. Most Active Players: Analysis by Amount Raised
16.3.8. Analysis by Geography
16.3.9. Most Active Players: Analysis by Number of Funding Instances
16.3.10. Most Active Players: Analysis by Amount Invested
16.4. Summary of Funding and Investments
17. PATENT ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. mRNA Vaccines: Patent Analysis
17.3.1. Analysis by Type of Patent
17.3.2. Analysis by Patent Publication Year
17.3.3. Analysis by Type of Patent and Publication Year
17.3.4. Analysis by Patent Application Year
17.3.5. Analysis by Patent Jurisdiction
17.3.6. Analysis by CPC Symbols
17.3.7. Analysis by Type of Applicant
17.3.8. Leading Industry Players: Analysis by Number of Patents
17.3.9. Leading Non-Industry Players: Analysis by Number of Patents
17.3.10. Leading Inventors: Analysis by Number of Patents
17.4. Patent Benchmarking Analysis
17.4.1. Analysis of Patent Characteristics
17.5. Patent Valuation
17.6. Leading Patents by Number of Citations
18. FDA APPROVAL STRATEGIES
18.1. Chapter Overview
18.2. Methodology
18.3. Key Parameters
18.4. General Reasons for Failure of Trials Focused on mRNA Vaccines
18.5. Benchmarking Analysis: Distribution of Key Strategies by mRNA Vaccines
19 OUTSOURCING: GO / NO-GO FRAMEWORK
19.1. Chapter Overview
19.2. Outsourcing: Go / No-Go Framework
19.3. mRNA Vaccines Outsourcing: Go / No-Go Framework
19.3.1. Key Parameters and Assumptions
19.3.2. Methodology
19.3.3. Results and Interpretations
19.3.3.1. Outsourcing: Go / No-Go Framework for Small Companies
19.3.3.2. Outsourcing: Go / No-Go Framework for Mid-Sized Companies
19.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies
20. MARKET IMPACT ANALYSIS
20.1. Chapter Overview
20.2. Market Drivers
20.3. Market Restraints
20.4. Market Opportunities
20.5. Market Challenges
20.6. Conclusion
21. GLOBAL mRNA VACCINES MARKET
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global mRNA Vaccines Market, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
21.3.1. Scenario Analysis
21.3.1.1. Conservative Scenario
21.3.1.2. Optimistic Scenario
21.4. Key Market Segmentations
22. mRNA VACCINES MARKET, BY TARGET INDICATION
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. mRNA Vaccines Market: Distribution by Target Indication
22.3.1. mRNA Vaccines Market for RSV Infection, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.3.2. mRNA Vaccines Market for Metastatic / R/ R Head and Neck Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.3.3. mRNA Vaccines Market for Influenza, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.3.4. mRNA Vaccines Market for Norovirus Acute Gastroenteritis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.3.5. mRNA Vaccines Market for Mononucleosis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. mRNA VACCINES MARKET, BY GEOGRAPHICAL REGIONS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. mRNA Vaccines Market: Distribution by Geographical Regions
23.3.1. mRNA Vaccines Market in North America, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.1.1. mRNA Vaccines Market in the US, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.1.2. mRNA Vaccines Market in Canada, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2. mRNA Vaccines Market in Europe, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.1. mRNA Vaccines Market in Germany, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.2. mRNA Vaccines Market in the France, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.3. mRNA Vaccines Market in Italy, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.4. mRNA Vaccines Market in UK, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.5. mRNA Vaccines Market in Spain, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.6. mRNA Vaccines Market in Rest of Europe, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3. mRNA Vaccines Market in Aisa-Pacific, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3.1. mRNA Vaccines Market in China, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3.2. mRNA Vaccines Market in Japan, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3.3. mRNA Vaccines Market in Australia, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3.4. mRNA Vaccines Market in South Korea, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.4. Penetration Growth (P-G) Matrix
23.3.5. Market Movement Analysis
23.4. Data Triangulation and Validation
24. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
24.1. mRNA Vaccines Market in North America: Distribution by Target Indication
24.1.1. mRNA Vaccines Market in North America for RSV Infection, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
24.1.2. mRNA Vaccines Market in North America for Metastatic / R/ R Head and Neck Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
24.1.3. mRNA Vaccines Market in North America for Influenza, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
24.1.4. mRNA Vaccines Market in North America for Norovirus Acute Gastroenteritis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
24.1.5. mRNA Vaccines Market in North America for Mononucleosis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25. MARKET OPPORTUNITY ANALYSIS: EUROPE
25.1. mRNA Vaccines Market in Europe: Distribution by Target Indication
25.1.1. mRNA Vaccines Market in Europe for RSV Infection, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25.1.2. mRNA Vaccines Market in Europe for Metastatic / R/ R Head and Neck Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25.1.3. mRNA Vaccines Market in Europe for Influenza, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25.1.4. mRNA Vaccines Market in Europe for Norovirus Acute Gastroenteritis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25.1.5. mRNA Vaccines Market in Europe for Mononucleosis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
26.1. mRNA Vaccines Market in Asia-Pacific: Distribution by Target Indication
26.1.1. mRNA Vaccines Market in Asia-Pacific for RSV Infection, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26.1.2. mRNA Vaccines Market in Asia-Pacific for Metastatic / R/ R Head and Neck Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26.1.3. mRNA Vaccines Market in Asia-Pacific for Influenza, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26.1.4. mRNA Vaccines Market in Asia-Pacific for Norovirus Acute Gastroenteritis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26.1.5. mRNA Vaccines Market in Asia-Pacific for Mononucleosis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
27. CONCLUDING REMARKS
28. EXECUTIVE INSIGHTS
28.1. Chapter Overview
28.2. Company A
28.2.1. Company Snapshot
28.2.2. Interview Transcript: Business Development Manager
28.3. Company B
28.3.1. Company Snapshot
28.3.2. Interview Transcript: Senior Director, Business Development
28.4. Company C
28.4.1. Company Snapshot
28.4.2. Interview Transcript: Team Leader
28.5. Company D
28.5.1. Company Snapshot
28.5.2. Interview Transcript: Director of Advanced Drug Delivery
28.6. Company E
28.6.1. Company Snapshot
28.6.2. Interview Transcript: Deputy Director
28.7. Company F
28.7.1. Company Snapshot
28.7.2. Interview Transcript: Co-founder and Chief Executive Officer
28.8. Company G
28.8.1. Company Snapshot
28.8.2. Interview Transcript: Co-founder
28.9. Company H
28.9.1. Company Snapshot
28.9.2. Interview Transcript: Chief Executive Officer
28.10. Company I
28.10.1. Company Snapshot
28.10.2. Interview Transcript: Chief Executive Officer
28.11. Company J
28.11.1. Company Snapshot
28.11.2. Interview Transcript: Chief Executive Officer
28.12. Company K
28.12.1. Company Snapshot
28.12.2. Interview Transcript: Chief Executive Officer
28.13. Company L
28.13.1. Company Snapshot
28.13.2. Interview Transcript: President
28.14. Company M
28.14.1. Company Snapshot
28.14.2. Interview Transcript: Medical Professional
29. APPENDIX 1: TABULATED DATA
30. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
圖表清單 List of Tables & Figures
Table 6.1 Differences Between Catheter Ablation and Surgical Ablation
Table 6.2 Types Of Catheter Ablation Techniques: Information on Mechanism Of Action, Advantages And Disadvantages
Table 7.1 List Of Pulsed Field Ablation Devices
Table 7.2 Pulsed Field Ablation Devices: Information On Shape Of Catheter, Configuration Of Catheter And Type Of Catheter (By Irrigation)
Table 7.3 Pulsed Field Ablation Devices: Information On Catheter Shaft Diameter, Number Of Electrodes And Electrical Polarity
Table 7.4 Pulsed Field Ablation Devices: Information On Source Of Ablation, Status Of Development, Phase Of Development Of Investigational Devices And Application
Table 7.5 Pulsed Field Ablation Devices: Information On Nct Number And Location Of Clinical Trial
Table 7.6 Pulsed Field Ablation Devices: Information On Target Indication And Target Therapeutic Area
Table 7.7 List Of Pulsed Field Ablation Device Developers
Table 9.1 Leading Developers Of Pulsed Field Ablation Systems
Table 9.2 Boston Scientific: Company Snapshot
Table 9.3 Boston Scientific: Pulsed Field Ablation Portfolio
Table 9.4 Boston Scientific: Recent Developments And Future Outlook
Table 9.5 Medtronic: Company Snapshot
Table 9.6 Medtronic: Pulsed Field Ablation Portfolio
Table 9.7 Medtronic: Recent Developments And Future Outlook
Table 9.8 Galvanize Therapeutics: Company Snapshot
Table 9.9 Galvanize Therapeutics: Pulsed Field Ablation Portfolio
Table 9.10 Galvanize Therapeutics: Recent Developments And Future Outlook
Table 9.11 Pulse Biosciences: Company Snapshot
Table 9.12 Pulse Biosciences: Pulsed Field Ablation Portfolio
Table 9.13 Pulse Biosciences: Recent Developments And Future Outlook
Table 9.14 Angiodynamics: Company Snapshot
Table 9.15 Angiodynamics: Pulsed Field Ablation Portfolio
Table 9.16 Angiodynamics: Recent Developments And Future Outlook
Table 9.17 Biosense Webster: Company Snapshot
Table 9.18 Biosense Webster: Pulsed Field Ablation Portfolio
Table 9.19 Biosense Webster: Recent Developments And Future Outlook
Table 9.20 Acutus Medical: Company Snapshot
Table 9.21 Acutus Medical: Pulsed Field Ablation Portfolio
Table 9.22 Acutus Medical: Recent Developments And Future Outlook
Table 9.23 Kardium: Company Snapshot
Table 9.24 Kardium: Pulsed Field Ablation Portfolio
Table 9.25 Kardium: Recent Developments And Future Outlook
Table 10.1 Abbott: Company Snapshot And Product Portfolio
Table 10.2 Accupulse Medical: Company Snapshot And Product Portfolio
Table 10.3 Argá Medtech: Company Snapshot And Product Portfolio
Table 10.4 Atrian Medical: Company Snapshot And Product Portfolio
Table 10.5 Aurigen Medical: Company Snapshot And Product Portfolio
Table 10.6 Cathrx: Company Snapshot And Product Portfolio
Table 10.7 Electrophysiology Frontiers: Company Snapshot And Product Portfolio
Table 10.8 Enchannel Medical: Company Snapshot And Product Portfolio
Table 10.9 Hangzhou Dinova Ep Technology: Company Snapshot And Product Portfolio
Table 10.10 Mirai Medical: Company Snapshot And Product Portfolio
Table 10.11 Tianjin Intelligent Health Medical: Company Snapshot And Product Portfolio
Table 11.1 Pulsed Field Ablation: List Of Partnerships And Collaborations
Table 11.2 Pulsed Field Ablation: List Of Funding And Investments
Table 12.1 Patent Analysis: Top Cpc Sections
Table 12.2 Patent Analysis: Top Cpc Symbols
Table 12.3 Patent Analysis: Top Cpc Codes
Table 12.4 Patent Analysis: Summary Of Benchmarking Analysis
Table 12.5 Patent Analysis: Categorization Based On Weighted Valuation Scores
Table 12.6 Patent Analysis: List Of Leading Patents (By Number Of Citations)
Table 13.1 Pulsed Field Ablation: List Of Global Events
Table 14.1 List Of Cardiac Mapping And Navigation Device Developers
Table 14.2 Likely Partner Analysis: Cardiac Mapping And Navigation Device Developers
Table 33.1 Pulsed Field Ablation Devices: Distribution By Product Components
Table 33.2 Pulsed Field Ablation Devices: Distribution By Shape Of Catheter
Table 33.3 Pulsed Field Ablation Devices: Distribution By Configuration Of Catheter
Table 33.4 Pulsed Field Ablation Devices: Distribution By Type Of Catheter (By Irrigation)
Table 33.5 Pulsed Field Ablation Devices: Distribution By Catheter Shaft Diameter (In Fr)
Table 33.6 Pulsed Field Ablation Devices: Distribution By Number Of Electrodes
Table 33.7 Pulsed Field Ablation Devices: Distribution By Electrical Polarity
Table 33.8 Pulsed Field Ablation Devices: Distribution By Source Of Ablation
Table 33.9 Pulsed Field Ablation Devices: Distribution By Status Of Development
Table 33.10 Pulsed Field Ablation Devices: Distribution By Status Of Development And Location Of Clinical Trial
Table 33.11 Pulsed Field Ablation Devices: Distribution By Application Area
Table 33.12 Pulsed Field Ablation Devices: Distribution By Target Therapeutic Area And Target Indication
Table 33.13 Pulsed Field Ablation Devices: Distribution By Status Of Development And Target Therapeutic Area
Table 33.14 Pulsed Field Ablation Devices: Distribution By Location Of Clinical Trial And Target Therapeutic Area
Table 33.15 Pulsed Field Ablation Devices: Distribution By Source Of Ablation, Application Area And Target Therapeutic Area
Table 33.16 Pulsed Field Ablation Device Developers: Distribution By Year Of Establishment
Table 33.17 Pulsed Field Ablation Device Developers: Distribution By Company Size
Table 33.18 Pulsed Field Ablation Device Developers: Distribution By Location Of Headquarters (Region)
Table 33.19 Pulsed Field Ablation Device Developers: Distribution By Location Of Headquarters (Country)
Table 33.20 Pulsed Field Ablation Device Developers: Distribution By Company Size And Location Of Headquarters (Region)
Table 33.21 Pulsed Field Ablation Device Developers: Distribution By Type Of Developer
Table 33.22 Pulsed Field Ablation Device Developers: Distribution By Company Ownership
Table 33.23 Pulsed Field Ablation Device Developers: Distribution By Company Ownership And Location Of Headquarters (Region)
Table 33.24 Most Active Players: Distribution By Number Of Products
Table 33.25 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered By Players Based In North America
Table 33.26 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered By Players Based In Europe
Table 33.27 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered By Players Based In Asia-Pacific
Table 33.28 Product Competitiveness Analysis Of Pulsed Field Ablation Devices: Competitiveness Score Of Top Products
Table 33.29 Boston Scientific: Financial Information
Table 33.30 Medtronic: Financial Information
Table 33.31 Angiodynamics: Financial Information
Table 33.32 Acutus Medical: Financial Information
Table 33.33 Partnerships And Collaborations: Cumulative Year-Wise Trend, Since 2022
Table 33.34 Partnerships And Collaborations: Distribution By Type Of Partnership
Table 33.35 Partnerships And Collaborations: Distribution By Year And Type Of Partnership
Table 33.36 Partnerships And Collaborations: Distribution By Type Of Product
Table 33.37 Partnerships And Collaborations: Distribution By Type Of Partnership And Type Of Product
Table 33.38 Partnerships And Collaborations: Distribution By Therapeutic Area
Table 33.39 Partnerships And Collaborations: Distribution By Type Of Partnership And Therapeutic Area
Table 33.40 Most Active Players: Distribution By Number Of Partnerships
Table 33.41 Partnerships And Collaborations: Intercontinental And Intracontinental Agreements
Table 33.42 Partnerships And Collaborations: Local And International Agreements
Table 33.43 Funding And Investments: Cumulative Year-Wise Trend Of Funding Instances, Since 2022
Table 33.44 Funding And Investments: Cumulative Year-Wise Trend Of Amount Invested, Since 2022
Table 33.45 Funding And Investments: Distribution Of Funding Instances By Type Of Funding
Table 33.46 Funding And Investments: Distribution Of Amount Invested By Type Of Funding (Usd Million)
Table 33.47 Funding And Investments: Distribution Of Funding Instances By Year And Type Of Funding
Table 33.48 Funding And Investments: Distribution Of Amount Invested By Year And Type Of Funding (Usd Million)
Table 33.49 Funding And Investments: Distribution Of Funding Instances And Amount Invested By Therapeutic Area
Table 33.50 Most Active Players: Distribution By Funding Instances
Table 33.51 Most Active Players: Distribution By Amount Raised
Table 33.52 Leading Investors: Distribution By Funding Instances
Table 33.53 Funding And Investments: Distribution Of Funding Instances And Amount Invested By Geography
Table 33.54 Patent Analysis: Distribution By Type Of Patent
Table 33.55 Patent Analysis: Cumulative Year-Wise Trend By Patent Application Year, Since 2022
Table 33.56 Patent Analysis: Cumulative Year-Wise Trend By Patent Publication Year, Since 2022
Table 33.57 Patent Analysis: Distribution By Type Of Patent And Patent Publication Year
Table 33.58 Patent Analysis: Distribution By Publication Time
Table 33.59 Patent Analysis: Distribution By Patent Jurisdiction
Table 33.60 Patent Analysis: Distribution By Type Of Applicant
Table 33.61 Patent Analysis: Distribution By Patent Age
Table 33.62 Leading Players: Distribution By Number Of Patents
Table 33.63 Leading Patent Assignees: Distribution By Number Of Patents
Table 33.64 Patent Benchmarking Analysis: Distribution Of Leading Industry Players By Patent Characteristics (Cpc Codes)
Table 33.65 Patent Benchmarking Analysis: Distribution Of Publication Time By Patent Characteristics (Cpc Codes)
Table 33.66 Pulsed Field Ablation: Patent Valuation
Table 33.67 Global Events Analysis: Cumulative Year-Wise Trend, Since 2018
Table 33.68 Global Events Analysis: Distribution By Type Of Event
Table 33.69 Global Events Analysis: Distribution By Year And Type Of Event
Table 33.70 Global Events Analysis: Distribution By Event Platform
Table 33.71 Global Events Analysis: Distribution By Location Of Event (Region)
Table 33.72 Global Events Analysis: Distribution By Location Of Event (Country)
Table 33.73 Word Cloud Analysis: Evolutionary Trends In Event Agenda / Key Focus Areas
Table 33.74 Most Active Event Organizers: Distribution By Number Of Events
Table 33.75 Most Active Participants: Distribution By Number Of Events
Table 33.76 Most Active Speakers: Distribution By Number Of Events
Table 33.77 Distribution By Designations Of Speakers
Table 33.78 Cardiac Mapping And Navigation Device Developers: Distribution By Year Of Establishment
Table 33.79 Cardiac Mapping And Navigation Device Developers: Distribution By Company Size
Table 33.80 Cardiac Mapping And Navigation Device Developers: Distribution By Location Of Headquarters (Region)
Table 33.81 Cardiac Mapping And Navigation Device Developers: Distribution By Location Of Headquarters (Country)
Table 33.82 Cardiac Mapping And Navigation Device Developers: Likely Partners Of Cardiac Pulsed Field Ablation Device Developers
Table 33.83 Global Pulsed Field Ablation Market, Historical Trends (Since 2018) And Future Estimates (Till 2035) (Usd Million)
Table 33.84 Global Pulsed Field Ablation Market, Forecasted Estimates (Till 2035), Scenario I (Usd Million)
Table 33.85 Global Pulsed Field Ablation Market, Forecasted Estimates (Till 2035), Scenario Ii (Usd Million)
Table 33.86 Global Pulsed Field Ablation Market, Forecasted Estimates (Till 2035), Scenario Iii (Usd Million)
Table 33.87 Pulsed Field Ablation Market: Distribution By Geography
Table 33.88 Pulsed Field Ablation Market In North America, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.89 Pulsed Field Ablation Market In Europe, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.90 Pulsed Field Ablation Market In Asia-Pacific, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.91 Pulsed Field Ablation Market: Distribution By Therapeutic Area
Table 33.92 Pulsed Field Ablation Market For Cardiovascular Disorders, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.93 Pulsed Field Ablation Market For Oncological Disorders, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.94 Pulsed Field Ablation Market For Respiratory Disorders, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.95 Pulsed Field Ablation Market For Dermatological Disorders, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.96 Pulsed Field Ablation Market: Distribution By Product Components
Table 33.97 Pulsed Field Ablation Market For Catheters, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.98 Pulsed Field Ablation Market For Generators, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.99 Pulsed Field Ablation Market For Cardiovascular Disorders: Distribution By Product Components
Table 33.100 Pulsed Field Ablation Market For Cardiovascular Disorders Using Catheters, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.101 Pulsed Field Ablation Market For Cardiovascular Disorders Using Generators, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.102 Pulsed Field Ablation Market For Cardiovascular Disorders: Distribution By Application Area
Table 33.103 Pulsed Field Ablation Market For Cardiovascular Disorders Using Ablation Devices, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035)
Table 33.104 Pulsed Field Ablation Market For Cardiovascular Disorders Using Ablation And Mapping Devices, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.105 Pulsed Field Ablation Market For Cardiovascular Disorders: Distribution By Source Of Ablation
Table 33.106 Pulsed Field Ablation Market For Cardiovascular Disorders Using Pf Energy-Based Devices, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.107 Pulsed Field Ablation Market For Cardiovascular Disorders Using Pf And Rf Energy-Based Devices, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.108 Pulsed Field Ablation Market For Cardiovascular Disorders Using Pf And Cryo Energy-Based Devices, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.109 Pulsed Field Ablation Market For Cardiovascular Disorders: Distribution By Geography
Table 33.110 Pulsed Field Ablation Market For Cardiovascular Disorders In North America, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.111 Pulsed Field Ablation Market For Cardiovascular Disorders In Us, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.112 Pulsed Field Ablation Market For Cardiovascular Disorders In Us: Distribution By Product Components, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.113 Pulsed Field Ablation Market For Cardiovascular Disorders In Us: Distribution By Application Area, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.114 Pulsed Field Ablation Market For Cardiovascular Disorders In Us: Distribution By Source Of Ablation, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.115 Pulsed Field Ablation Market For Cardiovascular Disorders In Canada, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.116 Pulsed Field Ablation Market For Cardiovascular Disorders In Canada: Distribution By Product Components, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.117 Pulsed Field Ablation Market For Cardiovascular Disorders In Canada: Distribution By Application Area, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.118 Pulsed Field Ablation Market For Cardiovascular Disorders In Canada: Distribution By Source Of Ablation, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.119 Pulsed Field Ablation Market For Cardiovascular Disorders In Europe, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.120 Pulsed Field Ablation Market For Cardiovascular Disorders In Europe: Distribution By Product Components, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.121 Pulsed Field Ablation Market For Cardiovascular Disorders In Europe: Distribution By Application Area, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.122 Pulsed Field Ablation Market For Cardiovascular Disorders In Europe: Distribution By Source Of Ablation, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.123 Pulsed Field Ablation Market For Cardiovascular Disorders In Asia-Pacific, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.124 Pulsed Field Ablation Market For Cardiovascular Disorders In China, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.125 Pulsed Field Ablation Market For Cardiovascular Disorders In China: Distribution By Product Components, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.126 Pulsed Field Ablation Market For Cardiovascular Disorders In China: Distribution By Application Area, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.127 Pulsed Field Ablation Market For Cardiovascular Disorders In China: Distribution By Source Of Ablation, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.128 Pulsed Field Ablation Market For Cardiovascular Disorders In Japan, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.129 Pulsed Field Ablation Market For Cardiovascular Disorders In Japan: Distribution By Product Components, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.130 Pulsed Field Ablation Market For Cardiovascular Disorders In Japan: Distribution By Application Area, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.131 Pulsed Field Ablation Market For Cardiovascular Disorders In Japan: Distribution By Source Of Ablation, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.132 Pulsed Field Ablation Market For Oncological Disorders: Distribution By Geography
Table 33.133 Pulsed Field Ablation Market For Oncological Disorders In North America, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.134 Pulsed Field Ablation Market For Oncological Disorders In Europe, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.135 Pulsed Field Ablation Market For Oncological Disorders In Asia-Pacific, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.136 Pulsed Field Ablation Market For Oncological Disorders: Distribution By Product Components
Table 33.137 Pulsed Field Ablation Market For Oncological Disorders Using Catheters, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.138 Pulsed Field Ablation Market For Oncological Disorders Using Generators, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.139 Pulsed Field Ablation Market For Oncological Disorders: Distribution By Type Of Cancer
Table 33.140 Pulsed Field Ablation Market For Soft-Tissue Ablative Cancers, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.141 Pulsed Field Ablation Market For Pancreatic Cancer, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.142 Pulsed Field Ablation Market For Prostate Cancer, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.143 Pulsed Field Ablation Market For Non-Small Cell Lung Cancer, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.144 Pulsed Field Ablation Market For Esophageal Cancer, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.145 Pulsed Field Ablation Market For Respiratory Disorders: Distribution By Geography
Table 33.146 Pulsed Field Ablation Market For Respiratory Disorders In North America, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.147 Pulsed Field Ablation Market For Respiratory Disorders In Europe, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.148 Pulsed Field Ablation Market For Respiratory Disorders In Asia-Pacific, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.149 Pulsed Field Ablation Market For Respiratory Disorders: Distribution By Product Components
Table 33.150 Pulsed Field Ablation Market For Respiratory Disorders Using Catheters, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.151 Pulsed Field Ablation Market For Respiratory Disorders Using Generators, Historical Trends (Since 2018) And Forecasted Estimates (Till 2035) (Usd Million)
Table 33.152 Boston Scientific: Pulsed Field Ablation Sales Forecast (Till 2035) (Usd Million)
Table 33.153 Medtronic: Pulsed Field Ablation Sales Forecast (Till 2035) (Usd Million)
Table 33.154 Galvanize Therapeutics: Pulsed Field Ablation Sales Forecast (Till 2035) (Usd Million)
Table 33.155 Angiodynamics: Pulsed Field Ablation Sales Forecast (Till 2035) (Usd Million)
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Recent Developments and Initiatives
Figure 5.3 Executive Summary: Patent Analysis
Figure 5.4 Executive Summary: Global Events Analysis
Figure 5.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Types of Ablation Techniques
Figure 6.2 Steps Involved in Pulsed Field Ablation
Figure 6.3 Various Parameters related to Ablative Energy Delivery
Figure 6.4 Historical Evolution of Pulsed Field Ablation Therapy
Figure 6.5 Mechanism of Action: Steps of Irreversible Electroporation
Figure 6.6 Advantages of Pulsed Field Ablation
Figure 7.1 Pulsed Field Ablation Devices: Distribution by Product Components
Figure 7.2 Pulsed Field Ablation Devices: Distribution by Shape of Catheter
Figure 7.3 Pulsed Field Ablation Devices: Distribution by Configuration of Catheter
Figure 7.4 Pulsed Field Ablation Devices: Distribution by Type of Catheter (by Irrigation)
Figure 7.5 Pulsed Field Ablation Devices: Distribution by Catheter Shaft Diameter (in Fr)
Figure 7.6 Pulsed Field Ablation Devices: Distribution by Number of Electrodes
Figure 7.7 Pulsed Field Ablation Devices: Distribution by Electrical Polarity
Figure 7.8 Pulsed Field Ablation Devices: Distribution by Source of Ablation
Figure 7.9 Pulsed Field Ablation Devices: Distribution by Status of Development
Figure 7.10 Pulsed Field Ablation Devices: Distribution by Status of Development and Location of Clinical Trial
Figure 7.11 Pulsed Field Ablation Devices: Distribution by Application Area
Figure 7.12 Pulsed Field Ablation Devices: Distribution by Target Therapeutic Area and Target Indication
Figure 7.13 Pulsed Field Ablation Devices: Distribution by Status of Development and Target Therapeutic Area
Figure 7.14 Pulsed Field Ablation Devices: Distribution by Location of Clinical Trial and Target Therapeutic Area
Figure 7.15 Pulsed Field Ablation Devices: Distribution by Source of Ablation, Application Area and Target Therapeutic Area
Figure 7.16 Pulsed Field Ablation Device Developers: Distribution by Year of Establishment
Figure 7.17 Pulsed Field Ablation Device Developers: Distribution by Company Size
Figure 7.18 Pulsed Field Ablation Device Developers: Distribution by Location of Headquarters (Region)
Figure 7.19 Pulsed Field Ablation Device Developers: Distribution by Location of Headquarters (Country)
Figure 7.20 Pulsed Field Ablation Device Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 7.21 Pulsed Field Ablation Device Developers: Distribution by Type of Developer
Figure 7.22 Pulsed Field Ablation Device Developers: Distribution by Company Ownership
Figure 7.23 Pulsed Field Ablation Device Developers: Distribution by Company Ownership and Location of Headquarters (Region)
Figure 7.24 Most Active Players: Distribution by Number of Products
Figure 8.1 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in North America
Figure 8.2 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in Europe
Figure 8.3 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in Asia-Pacific
Figure 8.4 Product Competitiveness Analysis of Pulsed Field Ablation Devices: Competitiveness Score of Top Products
Figure 9.1 Boston Scientific: Financial Information
Figure 9.2 Medtronic: Financial Information
Figure 9.3 AngioDynamics: Financial Information
Figure 9.4 Acutus Medical: Financial Information
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2022
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 11.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 11.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.7 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 11.8 Most Active Players: Distribution by Number of Partnerships
Figure 11.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.10 Partnerships and Collaborations: Local and International Agreements
Figure 11.11 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Since 2022
Figure 11.12 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Since 2022
Figure 11.13 Funding and Investments: Distribution of Funding Instances by Type of Funding
Figure 11.14 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 11.15 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
Figure 11.16 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 11.17 Funding and Investments: Distribution of Funding Instances and Amount Invested by Therapeutic Area
Figure 11.18 Most Active Players: Distribution by Funding Instances
Figure 11.19 Most Active Players: Distribution by Amount Raised
Figure 11.20 Leading Investors: Distribution by Funding Instances
Figure 11.21 Funding and Investments: Distribution of Funding Instances and Amount Invested by Geography
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Since 2022
Figure 12.3 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, Since 2022
Figure 12.4 Patent Analysis: Distribution by Type of Patent and Patent Publication Year
Figure 12.5 Patent Analysis: Distribution by Publication Time
Figure 12.6 Patent Analysis: Distribution by Patent Jurisdiction
Figure 12.7 Patent Analysis: Distribution by Type of Applicant
Figure 12.8 Patent Analysis: Distribution by Patent Age
Figure 12.9 Leading Players: Distribution by Number of Patents
Figure 12.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 12.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) Leading Industry Players
Figure 12.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Publication Time
Figure 12.13 Pulsed Field Ablation Devices: Patent Valuation
Figure 13.1 Global Events Analysis: Cumulative Year-wise Trend, Since 2022
Figure 13.2 Global Events Analysis: Distribution by Type of Event
Figure 13.3 Global Events Analysis: Distribution by Year and Type of Event
Figure 13.4 Global Events Analysis: Distribution by Event Platform
Figure 13.5 Global Events Analysis: Distribution by Location of Event (Region)
Figure 13.6 Global Events Analysis: Distribution by Location of Event (Country)
Figure 13.7 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Areas
Figure 13.8 Most Active Event Organizers: Distribution by Number of Events
Figure 13.9 Most Active Players: Distribution by Number of Events
Figure 13.10 Most Active Speakers: Distribution by Number of Events
Figure 13.11 Distribution by Designations of Speakers
Figure 14.1 Cardiac Mapping and Navigation Device Developers: Distribution by Year of Establishment
Figure 14.2 Cardiac Mapping and Navigation Device Developers: Distribution by Company Size
Figure 14.3 Cardiac Mapping and Navigation Device Developers: Distribution by Location of Headquarters (Region)
Figure 14.4 Cardiac Mapping and Navigation Device Developers: Distribution by Location of Headquarters (Country)
Figure 14.5 Cardiac Mapping and Navigation Device Developers: Likely Partners of Cardiac Pulsed Field Ablation Device Developers
Figure 16.1 Global Pulsed Field Ablation Market, Historical Trends (Since 2018) and Future Estimates (Till 2035) (USD Million)
Figure 16.2 Global Pulsed Field Ablation Market, Forecasted Estimates (Till 2035), Scenario I (USD Million)
Figure 16.3 Global Pulsed Field Ablation Market, Forecasted Estimates (Till 2035), Scenario II (USD Million)
Figure 16.4 Global Pulsed Field Ablation Market, Forecasted Estimates (Till 2035), Scenario III (USD Million)
Figure 16.5 Global Pulsed Field Ablation Market (Dynamic Dashboard Snippet)
Figure 17.1 Pulsed Field Ablation Market: Distribution by Geography
Figure 17.2 Pulsed Field Ablation Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million
Figure 17.3 Pulsed Field Ablation Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 17.4 Pulsed Field Ablation Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 17.5 Pulsed Field Ablation Market: Distribution by Geography (Dynamic Dashboard Snippet)
Figure 18.1 Pulsed Field Ablation Market: Distribution by Therapeutic Area
Figure 18.2 Pulsed Field Ablation Market for Cardiovascular Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 18.3 Pulsed Field Ablation Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 18.4 Pulsed Field Ablation Market for Respiratory Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 18.5 Pulsed Field Ablation Market for Dermatological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 18.6 Pulsed Field Ablation Market: Distribution by Therapeutic Area (Dynamic Dashboard Snippet)
Figure 19.1 Pulsed Field Ablation Market: Distribution by Product Components
Figure 19.2 Pulsed Field Ablation Market for Catheters, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 19.3 Pulsed Field Ablation Market for Generators, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 19.4 Pulsed Field Ablation Market: Distribution by Product Components (Dynamic Dashboard Snippet)
Figure 20.1 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Product Components
Figure 20.2 Pulsed Field Ablation Market for Cardiovascular Disorders using Catheters, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 20.3 Pulsed Field Ablation Market for Cardiovascular Disorders using Generators, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 20.4 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Product Components (Dynamic Dashboard Snippet)
Figure 21.1 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Application Area
Figure 21.2 Pulsed Field Ablation Market for Cardiovascular Disorders using Ablation Devices, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.3 Pulsed Field Ablation Market for Cardiovascular Disorders using Ablation and Mapping Devices, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.4 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Application Area (Dynamic Dashboard Snippet)
Figure 22.1 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Source of Ablation
Figure 22.2 Pulsed Field Ablation Market for Cardiovascular Disorders using PF Energy-based Devices, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 22.3 Pulsed Field Ablation Market for Cardiovascular Disorders using PF and RF Energy-based Devices, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 22.4 Pulsed Field Ablation Market for Cardiovascular Disorders using PF and Cryo Energy-based Devices, Historical Trends (Since 2018) and Forecasted Estimates(Till 2035) (USD Million)
Figure 22.5 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Source of Ablation (Dynamic Dashboard Snippet)
Figure 23.1 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Geography
Figure 23.2 Pulsed Field Ablation Market for Cardiovascular Disorders in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.3 Pulsed Field Ablation Market for Cardiovascular Disorders in US, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.4 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Product Components, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.5 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Application Area, Historical Trends (Since 2018) and Forecasted Estimates(Till 2035) (USD Million)
Figure 23.6 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Source of Ablation, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.7 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.8 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Product Components, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.9 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Application Area, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.10 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Source of Ablation, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.11 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.12 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Product Components, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.13 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Application Area, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.14 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Source of Ablation, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.15 Pulsed Field Ablation Market for Cardiovascular Disorders in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.16 Pulsed Field Ablation Market for Cardiovascular Disorders in China, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.17 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Product Components, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.18 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Application Area, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.19 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Source of Ablation, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.20 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.21 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Product Components, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.22 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Application Area, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.23 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Source of Ablation, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.24 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Region (Dynamic Dashboard Snippet)
Figure 24.1 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Geography
Figure 24.2 Pulsed Field Ablation Market for Oncological Disorders in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 24.3 Pulsed Field Ablation Market for Oncological Disorders in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 24.4 Pulsed Field Ablation Market for Oncological Disorders in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 24.5 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Geography (Dynamic Dashboard Snippet)
Figure 25.1 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Product Components
Figure 25.2 Pulsed Field Ablation Market for Oncological Disorders using Catheters, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 25.3 Pulsed Field Ablation Market for Oncological Disorders using Generators, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 25.4 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Product Components (Dynamic Dashboard Snippet)
Figure 26.1 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Type of Cancer
Figure 26.2 Pulsed Field Ablation Market for Soft-tissue Ablative Cancers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.3 Pulsed Field Ablation Market for Pancreatic Cancer, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.4 Pulsed Field Ablation Market for Prostate Cancer, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.5 Pulsed Field Ablation Market for Non-Small Cell Lung Cancer, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.6 Pulsed Field Ablation Market for Esophageal Cancer, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.7 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Type of Cancer (Dynamic Dashboard Snippet)
Figure 27.1 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Geography
Figure 27.2 Pulsed Field Ablation Market for Respiratory Disorders in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.3 Pulsed Field Ablation Market for Respiratory Disorders in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.4 Pulsed Field Ablation Market for Respiratory Disorders in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.5 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Geography (Dynamic Dashboard Snippet)
Figure 28.1 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Product Components
Figure 28.2 Pulsed Field Ablation Market for Respiratory Disorders using Catheters, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.3 Pulsed Field Ablation Market for Respiratory Disorders using Generators, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.4 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Product Components (Dynamic Dashboard Snippet)
Figure 29.1 Boston Scientific: Pulsed Field Ablation Sales Forecast (Till 2035) (USD Million)
Figure 29.2 Medtronic: Pulsed Field Ablation Sales Forecast (Till 2035) (USD Million)
Figure 29.3 Galvanize Therapeutics: Pulsed Field Ablation Sales Forecast (Till 2035) (USD Million)
Figure 29.4 AngioDynamics: Pulsed Field Ablation Sales Forecast (Till 2035) (USD Million)
Figure 30.1 Concluding Remarks: Overall Market Landscape
Figure 30.2 Concluding Remarks: Recent Developments
Figure 30.3 Concluding Remarks: Patent Analysis
Figure 30.4 Concluding Remarks: Global Events Analysis
Figure 30.5 Concluding Remarks: Market Forecast and Opportunity Analysis
提及公司
同分類最新報告（醫療器材）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們